← Back to Search

Behavioral Intervention

Social Media Messages Intervention Group for HIV Suppression (MAP Trial)

N/A
Waitlist Available
Led By Jacob J van den Berg, PhD
Research Sponsored by Brown University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test an intervention to increase use of treatment as prevention and pre-exposure prophylaxis among Black/African American and Hispanic/Latino MSM in the United States.

Eligible Conditions
  • HIV Suppression
  • Human Immunodeficiency Virus Infection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
treatment as prevention and pre-exposure prophylaxis uptake
Secondary study objectives
treatment as prevention and pre-exposure prophylaxis knowledge, attitudes, and behavioral intentions

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Social Media Messages Intervention GroupExperimental Treatment1 Intervention
Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website and theoretically-grounded social media messages.
Group II: Website Only GroupActive Control1 Intervention
Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website only.

Find a Location

Who is running the clinical trial?

Brown UniversityLead Sponsor
465 Previous Clinical Trials
698,866 Total Patients Enrolled
Centers for Disease Control and PreventionFED
887 Previous Clinical Trials
21,993,293 Total Patients Enrolled
Jacob J van den Berg, PhDPrincipal InvestigatorBrown University
~21 spots leftby Nov 2025